Peptides for Obesity: The Next Wave Beyond GLP-1
Medically reviewed by Dr. James Whitfield, DO, FACOI
While GLP-1 agonists have revolutionized obesity treatment, a new wave of peptides targeting different pathways is emerging, offering hope for even more effective and personalized weight loss solutions.
The Dawn of a New Era in Obesity Treatment
The landscape of obesity treatment has been dramatically reshaped by the advent of glucagon-like peptide-1 (GLP-1) receptor agonists. Medications like semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda) have demonstrated unprecedented efficacy in promoting weight loss, transforming the management of a condition that affects over a billion people worldwide. These therapies work by mimicking the effects of the natural GLP-1 hormone, which is released in the gut after eating. GLP-1 agonists enhance insulin secretion, slow down gastric emptying, and act on the brain to reduce appetite and increase feelings of fullness. The success of these drugs has been a game-changer, but the scientific community is already looking ahead to the next frontier of peptide-based therapies for obesity. Researchers are exploring novel pathways and combination therapies that promise even greater weight loss, improved metabolic health, and a more personalized approach to treatment.
The Rise of Dual and Triple Agonists: Tirzepatide and Retatrutide
The first wave of innovation beyond GLP-1 has come in the form of multi-receptor agonists, which target more than one hormonal pathway simultaneously. The most prominent example is tirzepatide (Mounjaro, Zepbound), a dual agonist that activates both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP is another incretin hormone that, like GLP-1, is involved in glucose regulation and appetite control. By targeting both pathways, tirzepatide has shown superior weight loss results compared to GLP-1 agonists alone. In clinical trials, patients taking tirzepatide achieved an average weight loss of up to 22.5% of their body weight, a figure that rivals the results of bariatric surgery [1].
Building on this success, researchers have developed retatrutide, a triple agonist that targets the GLP-1, GIP, and glucagon receptors. The addition of glucagon receptor agonism is particularly interesting. While glucagon is traditionally known for raising blood sugar levels, at therapeutic doses in combination with GLP-1 and GIP, it appears to increase energy expenditure and contribute to further weight loss. Phase 2 trials of retatrutide have shown even more remarkable results, with patients achieving an average weight loss of over 24% after 48 weeks [2]. These multi-agonist peptides represent a significant leap forward, demonstrating that a synergistic approach to targeting hormonal pathways can lead to profound and sustained weight loss.
Amylin Analogues: A Different Pathway to Satiety
Another promising class of peptides for obesity treatment is the amylin analogues. Amylin is a hormone that is co-secreted with insulin by the pancreatic beta cells. It plays a role in glucose regulation and appetite control by slowing gastric emptying, promoting satiety, and suppressing the post-meal rise in glucagon. Cagrilintide, a long-acting amylin analogue, has shown significant weight loss effects in clinical trials. When used in combination with a GLP-1 agonist like semaglutide, the results are even more impressive. A phase 1b trial of a cagrilintide-semaglutide combination (CagriSema) resulted in a weight loss of 15.6% after 20 weeks, suggesting a synergistic effect between the two peptides [3]. By targeting a different, complementary pathway to the incretin system, amylin analogues offer a valuable new tool in the fight against obesity.
Maridebart Cafraglutide (MariTide): A Novel Antibody-Peptide Conjugate
One of the most exciting recent developments is Maridebart cafraglutide (MariTide, formerly AMG 133), a novel antibody-peptide conjugate. This innovative molecule combines a GLP-1 receptor agonist with a monoclonal antibody that blocks the GIP receptor (GIPR). This dual mechanism is intriguing because it challenges the previous assumption that GIP receptor activation is always beneficial for weight loss. The GIPR antagonist antibody is thought to enhance the weight loss effects of the GLP-1 agonist, possibly by preventing the body from adapting to the GLP-1-induced changes. In a phase 2 study, MariTide demonstrated robust and sustained weight loss of up to 14.7% after 52 weeks, with the added benefit of less frequent dosing (monthly injections) [4]. This unique approach of combining agonism and antagonism in a single molecule opens up new possibilities for peptide-based therapies.
Comparison of Novel Peptide Therapies
| Peptide | Mechanism of Action | Average Weight Loss | Administration |
|---|---|---|---|
| Tirzepatide | GLP-1/GIP dual agonist | Up to 22.5% | Weekly injection |
| Retatrutide | GLP-1/GIP/Glucagon triple agonist | Over 24% | Weekly injection |
| Cagrilintide | Amylin analogue | ~10% (alone), >15% (with semaglutide) | Weekly injection |
| Maridebart Cafraglutide | GLP-1 agonist / GIPR antagonist | Up to 14.7% | Monthly injection |
Key Takeaways
The success of GLP-1 agonists has paved the way for a new generation of peptide-based therapies for obesity.
Dual and triple agonists like tirzepatide and retatrutide have demonstrated superior weight loss efficacy by targeting multiple hormonal pathways.
Amylin analogues such as cagrilintide offer a complementary approach to appetite control and satiety.
Novel antibody-peptide conjugates like Maridebart cafraglutide are exploring unique mechanisms of action, such as combining GLP-1 agonism with GIPR antagonism.
The future of obesity treatment lies in a multi-faceted approach, with a growing arsenal of peptides that can be tailored to individual patient needs.
> Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any peptide therapy or making changes to your health regimen.
---